Molecular signatures of lung cancer: Defining new diagnostic and therapeutic paradigms

Justin M. Balko, Carlos L. Arteaga

Research output: Contribution to journalReview article

1 Citation (Scopus)

Abstract

Molecular profiling holds great promise for improving our ability to diagnose, prognosticate, and select individualized treatments for lung cancer patients. However, using multidimensional data and novel technologies to derive these profiles is limited by our ability to employ the assay in a clinical scenario where it can impact the course of disease. Although many molecular signatures have been reported in lung cancer, as of yet, few have been sufficiently validated for widespread clinical use. Recently, several novel signatures have been reported, which address critical aspects of patient care and/or demonstrate improved efforts for appropriate clinical validation. Here, we present our opinion on the current state of the field of molecular signatures in lung cancer.

Original languageEnglish (US)
Pages (from-to)1-6
Number of pages6
JournalMolecular Diagnosis and Therapy
Volume16
Issue number1
DOIs
StatePublished - Mar 2 2012

Fingerprint

Lung Neoplasms
Patient Care
Therapeutics
Technology

ASJC Scopus subject areas

  • Medicine(all)
  • Molecular Medicine
  • Genetics
  • Pharmacology

Cite this

Molecular signatures of lung cancer : Defining new diagnostic and therapeutic paradigms. / Balko, Justin M.; Arteaga, Carlos L.

In: Molecular Diagnosis and Therapy, Vol. 16, No. 1, 02.03.2012, p. 1-6.

Research output: Contribution to journalReview article

@article{d442dba02aa14ddabf850dca42b437c2,
title = "Molecular signatures of lung cancer: Defining new diagnostic and therapeutic paradigms",
abstract = "Molecular profiling holds great promise for improving our ability to diagnose, prognosticate, and select individualized treatments for lung cancer patients. However, using multidimensional data and novel technologies to derive these profiles is limited by our ability to employ the assay in a clinical scenario where it can impact the course of disease. Although many molecular signatures have been reported in lung cancer, as of yet, few have been sufficiently validated for widespread clinical use. Recently, several novel signatures have been reported, which address critical aspects of patient care and/or demonstrate improved efforts for appropriate clinical validation. Here, we present our opinion on the current state of the field of molecular signatures in lung cancer.",
author = "Balko, {Justin M.} and Arteaga, {Carlos L.}",
year = "2012",
month = "3",
day = "2",
doi = "10.2165/11597430",
language = "English (US)",
volume = "16",
pages = "1--6",
journal = "Molecular Diagnosis and Therapy",
issn = "1177-1062",
publisher = "Adis International Ltd",
number = "1",

}

TY - JOUR

T1 - Molecular signatures of lung cancer

T2 - Defining new diagnostic and therapeutic paradigms

AU - Balko, Justin M.

AU - Arteaga, Carlos L.

PY - 2012/3/2

Y1 - 2012/3/2

N2 - Molecular profiling holds great promise for improving our ability to diagnose, prognosticate, and select individualized treatments for lung cancer patients. However, using multidimensional data and novel technologies to derive these profiles is limited by our ability to employ the assay in a clinical scenario where it can impact the course of disease. Although many molecular signatures have been reported in lung cancer, as of yet, few have been sufficiently validated for widespread clinical use. Recently, several novel signatures have been reported, which address critical aspects of patient care and/or demonstrate improved efforts for appropriate clinical validation. Here, we present our opinion on the current state of the field of molecular signatures in lung cancer.

AB - Molecular profiling holds great promise for improving our ability to diagnose, prognosticate, and select individualized treatments for lung cancer patients. However, using multidimensional data and novel technologies to derive these profiles is limited by our ability to employ the assay in a clinical scenario where it can impact the course of disease. Although many molecular signatures have been reported in lung cancer, as of yet, few have been sufficiently validated for widespread clinical use. Recently, several novel signatures have been reported, which address critical aspects of patient care and/or demonstrate improved efforts for appropriate clinical validation. Here, we present our opinion on the current state of the field of molecular signatures in lung cancer.

UR - http://www.scopus.com/inward/record.url?scp=84857586335&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84857586335&partnerID=8YFLogxK

U2 - 10.2165/11597430

DO - 10.2165/11597430

M3 - Review article

C2 - 22339590

AN - SCOPUS:84857586335

VL - 16

SP - 1

EP - 6

JO - Molecular Diagnosis and Therapy

JF - Molecular Diagnosis and Therapy

SN - 1177-1062

IS - 1

ER -